title: A global regulatory science agenda for vaccines.
abstract: The Decade of Vaccines Collaboration and development of the Global Vaccine Action Plan provides a catalyst and unique opportunity for regulators worldwide to develop and propose a global regulatory science agenda for vaccines. Regulatory oversight is critical to allow access to vaccines that are safe, effective, and of assured quality. Methods used by regulators need to constantly evolve so that scientific and technological advances are applied to address challenges such as new products and technologies, and also to provide an increased understanding of benefits and risks of existing products. Regulatory science builds on high-quality basic research, and encompasses at least two broad categories. First, there is laboratory-based regulatory science. Illustrative examples include development of correlates of immunity; or correlates of safety; or of improved product characterization and potency assays. Included in such science would be tools to standardize assays used for regulatory purposes. Second, there is science to develop regulatory processes. Illustrative examples include adaptive clinical trial designs; or tools to analyze the benefit-risk decision-making process of regulators; or novel pharmacovigilance methodologies. Included in such science would be initiatives to standardize regulatory processes (e.g., definitions of terms for adverse events [AEs] following immunization). The aim of a global regulatory science agenda is to transform current national efforts, mainly by well-resourced regulatory agencies, into a coordinated action plan to support global immunization goals. This article provides examples of how regulatory science has, in the past, contributed to improved access to vaccines, and identifies gaps that could be addressed through a global regulatory science agenda. The article also identifies challenges to implementing a regulatory science agenda and proposes strategies and actions to fill these gaps. A global regulatory science agenda will enable regulators, academics, and other stakeholders to converge around transformative actions for innovation in the regulatory process to support global immunization goals.
authors.affiliation: Health Canada, Ottawa, Canada.
authors.forename: Lindsay
authors.initials: L
authors.lastname: Elmgren
authors.forename: Xuguang
authors.initials: X
authors.lastname: Li
authors.forename: Carolyn
authors.initials: C
authors.lastname: Wilson
authors.forename: Robert
authors.initials: R
authors.lastname: Ball
authors.forename: Junzhi
authors.initials: J
authors.lastname: Wang
authors.forename: Klaus
authors.initials: K
authors.lastname: Cichutek
authors.forename: Michael
authors.initials: M
authors.lastname: Pfleiderer
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kato
authors.forename: Marco
authors.initials: M
authors.lastname: Cavaleri
authors.forename: James
authors.initials: J
authors.lastname: Southern
authors.forename: Teeranart
authors.initials: T
authors.lastname: Jivapaisarnpong
authors.forename: Philip
authors.initials: P
authors.lastname: Minor
authors.forename: Elwyn
authors.initials: E
authors.lastname: Griffiths
authors.forename: Yeowon
authors.initials: Y
authors.lastname: Sohn
authors.forename: David
authors.initials: D
authors.lastname: Wood
mesh_terms: D035843:Biomedical Research / Q000592:standards; D017277:Drug Approval; D033161:Government Regulation; D006801:Humans; D007391:International Cooperation; D060735:Pharmacovigilance; D011786:Quality Control; D014611:Vaccination / Q000331:legislation & jurisprudence*; D014612:Vaccines / Q000592:standards*
chemical_list: D014612:Vaccines